Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.

ABSTRACT:

Background

Immune-hemolytic anemia (IHA) is a rare immune-related adverse event (irAE) in cancer patients treated with immune-checkpoint inhibitors (ICIs). Although several cases of ICI-associated IHA have been reported, few attempts have been made to collate available information. This scoping review aims to provide a comprehensive description of the clinical features of ICI-associated IHA.

Methods

PubMed and Web of Science Core Collection databases were searched for articles published in English from January 2006 to January 2025 on ICI-associated IHA. Only full-text publications reporting the clinical characteristics of patients with ICI-associated IHA were included. Two authors independently assessed the search results for eligibility and extracted the following informati

SUBMITTER: Hernandez-Martinez JM 

PROVIDER: S-EPMC12268707 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature